Literature DB >> 2469732

Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease.

M A Alexander1, J Bennicelli, D Guerry.   

Abstract

The present studies were undertaken to characterize Ag presentation by cultured human melanoma cell lines. Cell lines established from "biologically early" lesions of malignant melanoma were able to present the soluble Ag tetanus toxoid (TT) to autologous and HLA-DR-matched allogeneic, TT-immune T cell clones. Proliferation of T cell clones in response to Ag presented by primary melanoma peaked on day 2 of culture with Ag. Ag presentation was blocked by pretreatment of TT-pulsed and fixed melanoma cells with mAb against HLA-DR, but not HLA-DQ, HLA-DP, or HLA-ABC. Ag processing and presentation were inhibited by treating the melanoma cells with ammonium chloride. In parallel with previous findings from this laboratory demonstrating the inability of cell lines cultured from "advanced" primary or metastatic melanoma to induce autologous T cell proliferation, such cell lines also failed to present this exogenous Ag despite the presence of cell-surface HLA-class II molecules. Thus, in contrast to the finding in biologically early melanoma, none of the multiple TT-immune, T cell clones from autologous patients or HLA-DR matched donors was able to respond to TT presented by melanoma cells cultured from advanced disease. Co-incubation studies revealed that metastatic melanoma cells did not secrete inhibitory substances during the APC assay, however, they were able to process TT, rendering it "immunogenic" in the presence of fixed, autologous non-T cells. When fixed, autologous melanoma cells were assayed for their ability to present processed Ag; fixed cells of early but not advanced disease were able to present Ag in this setting, indicating that the presenting limb becomes flawed in the evolution of the metastatic phenotype. Finally, studies of chloroquine inhibition of the capacity of melanoma cells derived from early primary disease to stimulate autologous peripheral blood T cells suggest that such cells process and present tumor-associated Ag in the same fashion as the "model" Ag TT.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469732

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Tumour-infiltrating lymphocytes in primary melanoma: functional consequences of differential IL-2 receptor expression.

Authors:  J C Becker; A Schwinn; R Dummer; G Burg; E B Bröcker
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

2.  Autophagic activity measured in whole rat hepatocytes as the accumulation of a novel BHMT fragment (p10), generated in amphisomes by the asparaginyl proteinase, legumain.

Authors:  Anders Øverbye; Frank Sætre; Linda Korseberg Hagen; Harald Thidemann Johansen; Per O Seglen
Journal:  Autophagy       Date:  2011-09-01       Impact factor: 16.016

Review 3.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

Review 4.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

Authors:  W W Overwijk; N P Restifo
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

5.  T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.

Authors:  Q Chen; M Smith; T Nguyen; D W Maher; P Hersey
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

6.  Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.

Authors:  T Morisaki; D L Morton; A Uchiyama; D Yuzuki; A Barth; D S Hoon
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

7.  Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.

Authors:  M K Jakobsen; N P Restifo; P A Cohen; F M Marincola; L B Cheshire; W M Linehan; S A Rosenberg; R B Alexander
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-05

8.  Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes.

Authors:  M Azizul Haque; Ping Li; Sheila K Jackson; Hassane M Zarour; John W Hawes; Uyen T Phan; Maja Maric; Peter Cresswell; Janice S Blum
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307

Review 9.  Overcoming Immune Evasion in Melanoma.

Authors:  Kevinn Eddy; Suzie Chen
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

10.  Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing.

Authors:  A M Nouri; R F Hussain; A V Dos Santos; M Mansouri; R T Oliver
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.